These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. FDA challenges stem-cell clinic. Cyranoski D Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009 [No Abstract] [Full Text] [Related]
7. FDA should stand firm on stem-cell treatments. Nature; 2016 Jul; 535(7610):7-8. PubMed ID: 27383946 [No Abstract] [Full Text] [Related]
8. Caution urged in trial of stem cells to treat spinal-cord injury. Barde Y Nature; 2009 Mar; 458(7234):29. PubMed ID: 19262651 [No Abstract] [Full Text] [Related]
9. Stem-cell therapy takes off in Texas. Cyranoski D Nature; 2012 Feb; 483(7387):13-4. PubMed ID: 22382952 [No Abstract] [Full Text] [Related]
10. Improving oversight of innovative medical interventions in Texas, USA. Levine AD Regen Med; 2012 Jul; 7(4):451-3. PubMed ID: 22817618 [No Abstract] [Full Text] [Related]
11. Texas stem cell rules may impede clinical research. Arnold C Lancet; 2012 May; 379(9828):1776. PubMed ID: 22586718 [No Abstract] [Full Text] [Related]
12. Texas legitimizes path around FDA oversight. DeFrancesco L Nat Biotechnol; 2012 May; 30(5):379. PubMed ID: 22565948 [No Abstract] [Full Text] [Related]
13. FDA regulation of adult stem cell therapies as used in sports medicine. Chirba MA; Sweetapple B; Hannon CP; Anderson JA J Knee Surg; 2015 Feb; 28(1):55-62. PubMed ID: 25603042 [TBL] [Abstract][Full Text] [Related]
14. Stem cell science: current ethical and policy issues. Mauron A; Jaconi ME Clin Pharmacol Ther; 2007 Sep; 82(3):330-3. PubMed ID: 17637783 [TBL] [Abstract][Full Text] [Related]